نتائج البحث - Fabrizio Cantini

تنقيح النتائج
  1. 1
    Baricitinib Therapy in Covid-19 Pneumonia — An Unmet Need Fulfilled

    Baricitinib Therapy in Covid-19 Pneumonia — An Unmet Need Fulfilled حسب Delia Goletti, Fabrizio Cantini

    منشور في 2021
    احصل على النص الكامل
    Carta
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Diagnosis of Latent Tuberculosis and Prevention of Reactivation in Rheumatic Patients Receiving Biologic Therapy: International Recommendations

    Diagnosis of Latent Tuberculosis and Prevention of Reactivation in Rheumatic Patients Receiving Biologic Therapy: International Recommendations حسب Florenzo Iannone, Fabrizio Cantini, Giovanni Lapadula

    منشور في 2014
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Adalimumab, Etanercept, Infliximab, and the Risk of Tuberculosis: Data from Clinical Trials, National Registries, and Postmarketing Surveillance

    Adalimumab, Etanercept, Infliximab, and the Risk of Tuberculosis: Data from Clinical Trials, National Registries, and Postmarketing Surveillance حسب Fabrizio Cantini, Laura Niccoli, Delia Goletti

    منشور في 2014
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Tuberculosis Risk in Patients Treated with Non-Anti-Tumor Necrosis Factor- (TNF- ) Targeted Biologics and Recently Licensed TNF- Inhibitors: Data from Clinical Trials and National Registries

    Tuberculosis Risk in Patients Treated with Non-Anti-Tumor Necrosis Factor- (TNF- ) Targeted Biologics and Recently Licensed TNF- Inhibitors: Data from Clinical Trials and National... حسب Fabrizio Cantini, Laura Niccoli, Delia Goletti

    منشور في 2014
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Sustained maintenance of clinical remission after adalimumab dose reduction in patients with early psoriatic arthritis: a long-term follow-up study

    Sustained maintenance of clinical remission after adalimumab dose reduction in patients with early psoriatic arthritis: a long-term follow-up study حسب Fabrizio Cantini, Niccoli Laura, Cassara, Kaloudi, Nannini Carlotta

    منشور في 2012
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: a randomized, prospective, long-term, follow-up study

    Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: a randomized, prospective, long-term, follow-up study حسب Fabrizio Cantini, Niccoli Laura, Cassara, Kaloudi, Nannini Carlotta

    منشور في 2013
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Successful treatment of SAPHO syndrome with infliximab: report of two cases

    Successful treatment of SAPHO syndrome with infliximab: report of two cases حسب Ignazio Olivieri, Angela Padula, Giovanni Ciancìo, Carlo Salvarani, Laura Niccoli, Fabrizio Cantini

    منشور في 2002
    احصل على النص الكامل احصل على النص الكامل
    Carta
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics

    Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics حسب Fabrizio Cantini, Carlotta Nannini, Laura Niccoli, Linda Petrone, Giuseppe Ippolito, Delia Goletti

    منشور في 2017
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  9. 9
    Preventive therapy for tuberculosis in rheumatological patients undergoing therapy with biological drugs

    Preventive therapy for tuberculosis in rheumatological patients undergoing therapy with biological drugs حسب Delia Goletti, Linda Petrone, Giuseppe Ippolito, Laura Niccoli, Carlotta Nannini, Fabrizio Cantini

    منشور في 2018
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  10. 10
    Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact

    Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact حسب Fabrizio Cantini, Laura Niccoli, Daniela Matarrese, Emanuele Nicastri, Paolo Stobbione, Delia Goletti

    منشور في 2020
    احصل على النص الكامل احصل على النص الكامل
    Carta
    أضف إلى المفضلة
    محفوظ في:
  11. 11
    Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review

    Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review حسب Fabrizio Cantini, Delia Goletti, Linda Petrone, Saeid Najafi Fard, Laura Niccoli, Rosario Foti

    منشور في 2020
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  12. 12
    Frequency and duration of clinical remission in patients with peripheral psoriatic arthritis requiring second-line drugs

    Frequency and duration of clinical remission in patients with peripheral psoriatic arthritis requiring second-line drugs حسب Fabrizio Cantini, Laura Niccoli, Carlotta Nannini, Emanuele Cassarà, P. Pasquetti, Ignazio Olivieri, Carlo Salvarani

    منشور في 2008
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  13. 13
    Immune-Guided Therapy of COVID-19

    Immune-Guided Therapy of COVID-19 حسب Gianfranco Ferraccioli, Elisa Gremese, Delia Goletti, Linda Petrone, Fabrizio Cantini, Stefano Ugel, Stefania Canè, Vincenzo Bronte

    منشور في 2022
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  14. 14
    HBV Reactivation in Patients Treated with Antitumor Necrosis Factor-Alpha (TNF-<i>α</i>) Agents for Rheumatic and Dermatologic Conditions: A Systematic Review and Meta-Analysis

    HBV Reactivation in Patients Treated with Antitumor Necrosis Factor-Alpha (TNF-<i>α</i>) Agents for Rheumatic and Dermatologic Conditions: A Systematic Review and Meta-Analysis حسب Fabrizio Cantini, Stefania Boccia, Delia Goletti, Florenzo Iannone, Emanuele Leoncini, Nikola Panić, Francesca Prignano, Giovanni Battista Gaeta

    منشور في 2014
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  15. 15
    Remitting seronegative symmetrical synovitis with pitting oedema (RS3PE) syndrome: a prospective follow up and magnetic resonance imaging study

    Remitting seronegative symmetrical synovitis with pitting oedema (RS3PE) syndrome: a prospective follow up and magnetic resonance imaging study حسب Fabrizio Cantini, Carlo Salvarani, Ignazio Olivieri, Libero Barozzi, Luigi Macchioni, Laura Niccoli, Angela Padula, Pietro Pavlica, Luigi Boiardi

    منشور في 1999
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  16. 16
    Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study

    Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study حسب Laura Niccoli, Carlotta Nannini, Maurizio Benucci, Daniela Chindamo, Emanuele Cassarà, Carlo Salvarani, Luca Cimino, Guido Gini, Ivo Lenzetti, Fabrizio Cantini

    منشور في 2007
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  17. 17
    ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents)

    ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble i... حسب John W. Baddley, Fabrizio Cantini, Delia Goletti, Juan J. Gómez‐Reino, Eleftherios Mylonakis, Rafael San Juan, Mario Fernández‐Ruiz, Julián Torre‐Cisneros

    منشور في 2018
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  18. 18
    Cervical interspinous bursitis in active polymyalgia rheumatica

    Cervical interspinous bursitis in active polymyalgia rheumatica حسب Carlo Salvarani, Libero Barozzi, Fabrizio Cantini, Laura Niccoli, Luigi Boiardi, Massimo Valentino, Nicolò Pipitone, Gianluigi Bajocchi, Pierluigi Macchioni, Mariagrazia Catanoso, Ignazio Olivieri, Gene G. Hunder

    منشور في 2008
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  19. 19
    Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumab

    Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumab حسب Désirée van der Heijde, Maxime Bréban, D Halter, Gino DiVittorio, Johan Bratt, Fabrizio Cantini, S. Kary, Aileen L. Pangan, H. Küpper, Suchitrita S. Rathmann, Joachim Sieper, Phillip J. Mease

    منشور في 2014
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  20. 20
    The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy

    The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional... حسب Ignazio Olivieri, S De Portu, Carlo Salvarani, Alberto Cauli, Ennio Lubrano, Antonio Spadaro, Fabrizio Cantini, Maria Stefania Cutro, Alessandro Mathieu, Marco Matucci‐Cerinic, N. Pappone, Leonardo Punzi, Raffaele Scarpa, LG Mantovani

    منشور في 2008
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: